Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Method for treating multiloculated hydrocephalus by administering an anti-il6 receptor antibody
US2017291950A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017291950-A1 |
| Application number | US-201715483231-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 10, 2017 |
| Priority date | Apr 8, 2016 |
| Publication date | Oct 12, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention is directed to a method of treating multiloculated hydrocephalus comprising administering to a subject who is suffering from multiloculated hydrocephalus an antibody that binds to an IL-6 receptor.
First claim
Opening claim text (preview).
1 . A method for treating or reducing the severity of multiloculated hydrocephalus comprising administering to a subject, who is suffering from multiloculated hydrocephalus, an antibody that binds to an IL-6 receptor. 2 . The method of claim 1 , wherein the subject is human. 3 . The method of claim 1 , wherein the subject is a human in utero or no more than two years of age. 4 . The method of claim 1 , wherein the subject is human and wherein the antibody that binds to the IL-6 receptor is a humanized monoclonal antibody. 5 . The method of claim 1 , wherein the humanized monoclonal antibody crossblocks binding of Tocilziumab to the IL-6 receptor. 6 . The method of claim 1 , wherein the antibody that binds to the IL-6 receptor is Tocilziumab. 7 . The method of claim 1 that comprises intracerebroventricularly, intracerebrally, or intrathecally administering the antibody that binds to an IL-6 receptor. 8 . The method of claim 1 that comprises administering the antibody that binds to IL-6 receptor in an amount that reduces the level of IL-6 in the cerebrospinal fluid of the subject compared to the level in a control subject to whom the antibody was not administered. 9 . The method of claim 1 , further comprising administering at least one STAT3 inhibitor or other IL-6 antagonist. 10 . The method of claim 1 , further comprising administering an antibody that binds to IL-6. 11 . A method for preventing multiloculated hydrocephalus comprising administering an antibody to an IL-6 receptor to a subject who has been diagnosed with meningitis or intraventricular hemorrhage. 12 . The method of claim 11 , wherein the subject is human. 13 . The method of claim 11 , wherein the subject is a human in utero or no more than two years of age. 14 . The method of claim 11 , wherein the subject is human and wherein the antibody that binds to the IL-6 receptor is a humanized monoclonal antibody. 15 . The method of claim 11 , wherein the humanized monoclonal antibody crossblocks binding of Tocilziumab to the IL-6 receptor. 16 . The method of claim 11 , wherein the antibody that binds to the IL-6 receptor is Tocilziumab. 17 . The method of claim 11 that comprises intracerebroventricularly, intracerebrally, or intrathecally administering the antibody that binds to an IL-6 receptor. 18 . The method of claim 11 that comprises administering the antibody that binds to IL-6 receptor in an amount that reduces the level of IL-6 in the cerebrospinal fluid of the subject compared to the level in a control subject to whom the antibody was not administered. 19 . The method of claim 11 , further comprising administering at least one STAT3 inhibitor or other IL-6 antagonist. 20 . The method of claim 11 , further comprising administering an antibody that binds to IL-6.
Assignees
Inventors
Classifications
IL-6 · CPC title
- A61K45/06Primary
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
- C07K16/2866Primary
against receptors for cytokines, lymphokines, interferons · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017291950A1 cover?
- The invention is directed to a method of treating multiloculated hydrocephalus comprising administering to a subject who is suffering from multiloculated hydrocephalus an antibody that binds to an IL-6 receptor.
- Who is the assignee on this patent?
- Univ Imam Abdulrahman Bin Faisal
- What technology area does this patent fall under?
- Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Oct 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).